Gilead Sciences — CureCurrent

Published trials482

Recruiting shown10

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Study of GS-0415 and How It Works in People With HIVNCT07719491 · lead sponsor · 2026-07-22

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961 · lead sponsor · 2026-07-14

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778 · lead sponsor · 2026-03-17

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNCT06926920 · lead sponsor · 2025-04-30

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · lead sponsor · 2025-04-04

First in Human Study of TUB-030 in Patients With Advanced Solid TumorsNCT06657222 · lead sponsor · 2024-12-13

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)NCT06562907 · lead sponsor · 2024-08-28

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsNCT06337032 · lead sponsor · 2024-08-27

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCNCT06303505 · lead sponsor · 2024-06-12

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · lead sponsor · 2022-12-12

Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung CancerNCT07806773 · lead sponsor · 2026-11-01

NOT_YET_RECRUITING

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451 · lead sponsor · 2025-08-12

ACTIVE_NOT_RECRUITING

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716 · lead sponsor · 2025-07-22

ACTIVE_NOT_RECRUITING

Study of GS-0151 in Participants With Rheumatoid ArthritisNCT06902519 · lead sponsor · 2025-05-14

ACTIVE_NOT_RECRUITING

A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in SpainNCT06683482 · lead sponsor · 2025-02-21

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · lead sponsor · 2024-10-07

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · lead sponsor · 2023-12-13

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · lead sponsor · 2023-11-17

ACTIVE_NOT_RECRUITING

Study of GS-0272 in Participants With Rheumatoid ArthritisNCT06031415 · lead sponsor · 2023-09-28

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · lead sponsor · 2023-05-08

ACTIVE_NOT_RECRUITING

Study of Novel Treatment Combinations in Patients With Lung CancerNCT05633667 · lead sponsor · 2023-03-16

ACTIVE_NOT_RECRUITING

Study With Various Immunotherapy Treatments in Participants With Lung CancerNCT05676931 · lead sponsor · 2023-02-21

ACTIVE_NOT_RECRUITING

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237 · lead sponsor · 2022-10-12

ACTIVE_NOT_RECRUITING

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsNCT05458102 · lead sponsor · 2022-08-19

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · lead sponsor · 2022-07-25

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · lead sponsor · 2022-07-20

ACTIVE_NOT_RECRUITING

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) TreatmentNCT05165771 · lead sponsor · 2022-07-01

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenNCT05281510 · lead sponsor · 2022-06-09

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974 · lead sponsor · 2022-05-30

ACTIVE_NOT_RECRUITING

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04958785 · lead sponsor · 2021-12-14

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734 · lead sponsor · 2021-11-17

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096 · lead sponsor · 2021-10-20

ACTIVE_NOT_RECRUITING

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996 · lead sponsor · 2021-10-05

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509 · lead sponsor · 2021-08-30

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionNCT04925752 · lead sponsor · 2021-06-28

ACTIVE_NOT_RECRUITING

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986 · lead sponsor · 2020-11-23

ACTIVE_NOT_RECRUITING

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsNCT04608344 · lead sponsor · 2020-11-04

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsNCT04454437 · lead sponsor · 2020-10-23

ACTIVE_NOT_RECRUITING

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594 · lead sponsor · 2019-11-22

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165 · lead sponsor · 2019-07-24

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645 · lead sponsor · 2019-06-28

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerNCT03901339 · lead sponsor · 2019-05-08

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866 · lead sponsor · 2018-11-26

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionNCT03417778 · lead sponsor · 2018-04-03

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusNCT03472326 · lead sponsor · 2018-04-03

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455 · lead sponsor · 2017-11-07

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380 · lead sponsor · 2017-06-12

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447 · lead sponsor · 2017-05-09

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeNCT03100942 · lead sponsor · 2017-05-01

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerNCT02983604 · lead sponsor · 2017-01-10

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisNCT02862574 · lead sponsor · 2016-12-15

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateNCT02885181 · lead sponsor · 2016-09-21

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02889796 · lead sponsor · 2016-08-30

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyNCT02886728 · lead sponsor · 2016-08-08

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerNCT02161679 · lead sponsor · 2016-08-01

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentNCT02873936 · lead sponsor · 2016-07-27

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601 · lead sponsor · 2016-04-01

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)NCT02626026 · lead sponsor · 2016-01-26

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsNCT02616783 · lead sponsor · 2015-12-22

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerNCT02607228 · lead sponsor · 2015-12-08

Sponsor roles

collaborator268

lead sponsor214

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.